QUOTE AND NEWS
Benzinga  Jan 21  Comment 
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) were trading higher by 0.62 percent during Thursday's afternoon. Halozyme Therapeutics disclosed earlier in the day that AbbVie Inc (NYSE: ABBV) has dosed its first subject in a clinical...
Motley Fool  Jan 9  Comment 
It was a banner year for the human enzyme specialist.
GenEng News  Dec 21  Comment 
Halozyme Therapeutics said today it will partner with Eli Lilly to develop and commercialize products that combine the pharma giant’s compounds with Halozyme's ENHANZE™ platform. The deal could generate up to $800 million for...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki